Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interleukin-2 as a modulator of 5-fluorouracil in hepatic arterial immunochemotherapy for liver metastases
Autore:
Okuno, K; Hirai, N; Takemoto, Y; Kawai, I; Yasutomi, M;
Indirizzi:
Kinki Univ, Sch Med, Dept Surg 1, Osaka 5898511, Japan Kinki Univ Osaka Japan 5898511 ch Med, Dept Surg 1, Osaka 5898511, Japan Kyowa Hakko Kogyo Co Ltd, Analyt Res Ctr, Fuji Plant, Sizuoka, Japan KyowaHakko Kogyo Co Ltd Sizuoka Japan Ctr, Fuji Plant, Sizuoka, Japan
Titolo Testata:
HEPATO-GASTROENTEROLOGY
fascicolo: 32, volume: 47, anno: 2000,
pagine: 487 - 491
SICI:
0172-6390(200003/04)47:32<487:IAAMO5>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED TRIAL; COLORECTAL-CARCINOMA; KUPFFER CELLS; CANCER; FLOXURIDINE; INFUSION; INVIVO; LINE;
Keywords:
hepatic arterial infusion; interleukin-2; 5-fluorouracil; biochemical modulation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Okuno, K Kinki Univ, Sch Med, Dept Surg 1, 377-2 Ohno Higashi, Osaka 5898511, Japan Kinki Univ 377-2 Ohno Higashi Osaka Japan 5898511 5898511, Japan
Citazione:
K. Okuno et al., "Interleukin-2 as a modulator of 5-fluorouracil in hepatic arterial immunochemotherapy for liver metastases", HEP-GASTRO, 47(32), 2000, pp. 487-491

Abstract

Background/Aims: Hepatic arterial infusion of interleukin-2-based immunochemotherapy has yielded a high response rate (>75%) in patients with unresectable liver metastases. In order to clarify the mechanisms that underlie the apparent benefit of combination treatment, the role of IL-2 as a modulator of 5-fluorouracil metabolism was investigated. Methodology: A single dose of Ei-fluorouracil (50mg/kg) with or without IL-2 (3500 Japan Reference Units/kg) was given via the hepatic artery to ratsbearing liver metastases. Thirty minutes later samples of liver metastaticfoci or surrounding normal liver tissue were removed for the measurement of thymidylate synthase, thymidine kinase and dihydropyrimidine dehydrogenase activity, and 5-fluorouracil content. Results: 5-fluorouracil levels in tumor were significantly higher than in normal liver. Although the addition of IL-2 reduced 5-fluorouracil levels in both tumor and normal liver tissues by the activation of dihydropyrimidine dehydrogenase, the ratio of tumor/normal liver 5-fluorouracil levels was unchanged. Both thymidylate synthase and thymidine kinase activities were significantly inhibited in tumor tissue when the combination of 5-fluorouracil and IL-2 was administered. Conclusions: IL-2 increases 5-fluorouracil cytotoxicity through the inhibition of thymidylate synthase/thymidine kinase activities in the hepatic arterial infusion.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 01:51:30